학술논문
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS242-TPS242, 235p
Subject
Language
ISSN
0732183X